Occam’s UK Biotech Practice Accelerates with Placement of CSO at Nucleome
Occam’s traction in the UK biotech market continues to grow with the placement of Steve Harrison, an accomplished global entrepreneurial drug hunter, as CSO of Nucleome Therapeutics, an Oxford spin out and M Ventures/J&J Innovation/Pfizer Ventures/OSE/British Patient Capital investment exploring the dark genome for therapeutic opportunities.
Harrison has three decades of experience in the biotechnology sector, with leadership experience at product-driven research organizations at all stages, from target identification to new drug registration and clinical development in multiple therapeutic areas, including immunotherapeutics, oncology, rare diseases, and pain management.
Prior to Nucleome, Harrison held executive leadership positions at several biotechnology companies in the San Francisco Bay Area, most recently as Chief Scientific Officer of Engine Biosciences. Previous roles include Chief Scientific Officer and Senior Vice President at Relypsa (divested to Galencia for $1.53 billion in 2016).
Recent Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.